NASDAQ:AMAG - AMAG Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $12.60 -0.07 (-0.55 %) (As of 03/18/2019 01:55 PM ET)Previous Close$12.67Today's Range$12.55 - $12.8552-Week Range$10.70 - $26.10Volume47,425 shsAverage Volume776,357 shsMarket Capitalization$437.38 millionP/E Ratio-3.25Dividend YieldN/ABeta0.44 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email AMAG Pharmaceuticals, Inc., a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. The company also offers Cord Blood Registry services that are related to the collection, processing, and storage of umbilical cord blood and cord tissue units for pregnant women and their families. In addition, it has an option agreement with Velo Bio LLC to acquire the rights to digoxin immune fab, a polyclonal antibody, which is in Phase IIb/IIIa trial for the treatment of severe preeclampsia in pregnant women. The company sells Feraheme to authorized wholesalers and specialty distributors. It has a license agreement with Palatin Technologies, Inc. to research, develop, and commercialize Bremelanotide, an investigational product for the treatment of hypoactive sexual desire disorder (HSDD) in pre-menopausal women, as well as with Endoceutics, Inc. to develop and commercialize pharmaceutical products with dehydroepiandrosterone; and development and license agreement with Antares Pharma, Inc. to develop, use, sell, offer for sale, and import and export the Makena auto-injector. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts. Receive AMAG News and Ratings via Email Sign-up to receive the latest news and ratings for AMAG and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:AMAG Previous Symbol CUSIP00163U10 CIK792977 Webwww.amagpharma.com Phone617-498-3300Debt Debt-to-Equity Ratio0.35 Current Ratio3.17 Quick Ratio3.01Price-To-Earnings Trailing P/E Ratio-3.25 Forward P/E Ratio-4.13 P/E GrowthN/A Sales & Book Value Annual Sales$474 million Price / Sales0.92 Cash Flow$1.5385 per share Price / Cash Flow8.19 Book Value$21.62 per share Price / Book0.58Profitability EPS (Most Recent Fiscal Year)($3.88) Net Income$-65,760,000.00 Net Margins-13.07% Return on Equity-17.10% Return on Assets-8.41%Miscellaneous EmployeesN/A Outstanding Shares34,713,000Market Cap$437.38 million Next Earnings Date5/2/2019 (Estimated) OptionableOptionable AMAG Pharmaceuticals (NASDAQ:AMAG) Frequently Asked Questions What is AMAG Pharmaceuticals' stock symbol? AMAG Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMAG." How were AMAG Pharmaceuticals' earnings last quarter? AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) posted its quarterly earnings data on Thursday, February, 7th. The specialty pharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.98) by $0.38. The specialty pharmaceutical company earned $88.10 million during the quarter, compared to the consensus estimate of $95.21 million. AMAG Pharmaceuticals had a negative net margin of 13.07% and a negative return on equity of 17.10%. AMAG Pharmaceuticals's quarterly revenue was down 31.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.10 EPS. View AMAG Pharmaceuticals' Earnings History. When is AMAG Pharmaceuticals' next earnings date? AMAG Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, May 2nd 2019. View Earnings Estimates for AMAG Pharmaceuticals. What guidance has AMAG Pharmaceuticals issued on next quarter's earnings? AMAG Pharmaceuticals updated its FY 2019 earnings guidance on Thursday, February, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $365-415 million, compared to the consensus revenue estimate of $382.51 million. What price target have analysts set for AMAG? 8 analysts have issued 1-year target prices for AMAG Pharmaceuticals' stock. Their forecasts range from $14.00 to $24.65. On average, they anticipate AMAG Pharmaceuticals' stock price to reach $20.2063 in the next year. This suggests a possible upside of 60.4% from the stock's current price. View Analyst Price Targets for AMAG Pharmaceuticals. What is the consensus analysts' recommendation for AMAG Pharmaceuticals? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AMAG Pharmaceuticals in the last year. There are currently 1 sell rating, 6 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AMAG Pharmaceuticals. What are Wall Street analysts saying about AMAG Pharmaceuticals stock? Here are some recent quotes from research analysts about AMAG Pharmaceuticals stock: 1. Cantor Fitzgerald analysts commented, ": We reiterate our Neutral rating and are lowering our PT to $14 from $17. Failure of the post-approval Makena trial is a clear setback for the company. We suspect investors may be increasingly drawn to the stock as one to own given the subsequent devaluation, but that longer-term investing requires some framing of the commercial impact. We believe the trial result reinforces the importance of the next 12-18 months for AMAG to demonstrate that existing and pipeline assets can adequately replace lost Makena revenue." (3/14/2019) 2. According to Zacks Investment Research, "In July, AMAG’s drug, Makena’s generic hit the market, which pulled down its sales. AMAG’s other drug Feraheme currently competes with IV iron replacement therapies like Venofer, Injectafer, Ferrlecit and their generic versions, among others. This could further limit sales. However, the company divested the Cord Blood Registry (CBR) business and strengthened its balance sheet;. It acquired AMAG-423, which is an orphan drug for the potential treatment of severe preeclampsia; and launched the Intrarosa direct-to-consumer campaign. AMAG is prepared for the upcoming FDA advisory committee meeting for Vyleesi (bremelanotide). Shares of the company have outperformed the industry year to date. Loss estimates have widenede ahead of the Q4 results. The company has mixed earnings surprise in the last few quarters." (1/23/2019) Has AMAG Pharmaceuticals been receiving favorable news coverage? Media coverage about AMAG stock has trended somewhat positive on Monday, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AMAG Pharmaceuticals earned a news sentiment score of 1.1 on InfoTrie's scale. They also assigned headlines about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future. Who are some of AMAG Pharmaceuticals' key competitors? Some companies that are related to AMAG Pharmaceuticals include Xencor (XNCR), Hexo (HEXO), Rhoen Klinikum (RHK), Healius (HLS), Allakos (ALLK), Zai Lab (ZLAB), Wave Life Sciences (WVE), Pacira Pharmaceuticals (PCRX), STAAR Surgical (STAA), Primary Health Care (PRY), Genus (GNS), Myovant Sciences (MYOV), Opko Health (OPK), Mazor Robotics (MZOR) and Magellan Health (MGLN). What other stocks do shareholders of AMAG Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other AMAG Pharmaceuticals investors own include Celgene (CELG), Bausch Health Companies (BHC), Broadcom (AVGO), Gilead Sciences (GILD), Tesla (TSLA), Netflix (NFLX), Skyworks Solutions (SWKS), Energy Transfer LP Unit (ET), Alibaba Group (BABA) and bluebird bio (BLUE). Who are AMAG Pharmaceuticals' key executives? AMAG Pharmaceuticals' management team includes the folowing people: Dr. William K. Heiden, CEO, Pres & Director (Age 59)Mr. Edward H. Myles, Exec. VP & CFO (Age 47)Mr. Joseph D. Vittiglio, Exec. VP of Legal Affairs and Quality, Gen. Counsel & Sec. (Age 47)Dr. Julie Krop, Exec. VP of Devel. & Chief Medical Officer (Age 53)Mr. Nicholas Grund, Exec. VP & Chief Commercial Officer (Age 49) Who are AMAG Pharmaceuticals' major shareholders? AMAG Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Robeco Institutional Asset Management B.V. (3.55%), D. E. Shaw & Co. Inc. (3.00%), Connor Clark & Lunn Investment Management Ltd. (2.02%), Royce & Associates LP (1.93%), Great Point Partners LLC (1.92%) and Acadian Asset Management LLC (1.57%). Company insiders that own AMAG Pharmaceuticals stock include Joseph Vittiglio, Julie Krop and William K Heiden. View Institutional Ownership Trends for AMAG Pharmaceuticals. Which major investors are selling AMAG Pharmaceuticals stock? AMAG stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Millennium Management LLC, Hourglass Capital LLC, Acadian Asset Management LLC, State Board of Administration of Florida Retirement System, Macquarie Group Ltd., GSA Capital Partners LLP and Voce Capital Management LLC. Company insiders that have sold AMAG Pharmaceuticals company stock in the last year include Joseph Vittiglio and William K Heiden. View Insider Buying and Selling for AMAG Pharmaceuticals. Which major investors are buying AMAG Pharmaceuticals stock? AMAG stock was purchased by a variety of institutional investors in the last quarter, including Great Point Partners LLC, Royce & Associates LP, Norges Bank, Robeco Institutional Asset Management B.V., Canada Pension Plan Investment Board, Monashee Investment Management LLC, Two Sigma Investments LP and Squarepoint Ops LLC. View Insider Buying and Selling for AMAG Pharmaceuticals. How do I buy shares of AMAG Pharmaceuticals? Shares of AMAG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is AMAG Pharmaceuticals' stock price today? One share of AMAG stock can currently be purchased for approximately $12.60. How big of a company is AMAG Pharmaceuticals? AMAG Pharmaceuticals has a market capitalization of $437.38 million and generates $474 million in revenue each year. The specialty pharmaceutical company earns $-65,760,000.00 in net income (profit) each year or ($3.88) on an earnings per share basis. What is AMAG Pharmaceuticals' official website? The official website for AMAG Pharmaceuticals is http://www.amagpharma.com. How can I contact AMAG Pharmaceuticals? AMAG Pharmaceuticals' mailing address is 1100 WINTER STREET, WALTHAM MA, 02451. The specialty pharmaceutical company can be reached via phone at 617-498-3300 or via email at [email protected] MarketBeat Community Rating for AMAG Pharmaceuticals (NASDAQ AMAG)Community Ranking: 2.1 out of 5 ( )Outperform Votes: 329 (Vote Outperform)Underperform Votes: 439 (Vote Underperform)Total Votes: 768MarketBeat's community ratings are surveys of what our community members think about AMAG Pharmaceuticals and other stocks. Vote "Outperform" if you believe AMAG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMAG will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/18/2019 by MarketBeat.com StaffFeatured Article: What is a Derivative?